Thirteen patients with AIDS or ARC on continuous zidovudine therapy (800-1200mg daily), who developed severe anaemia (median Hb 7.9g dl-1 range 4.9-9.4) after 66 days of treatment (median, range 35-258) were then treated with an il"termittent regimen in an open study. The regimen c(j)'tsisted of cycles of 4 weeks on treatment (600-100mg'daily) followed by 2 weeks off. Intermittent treatment was tolerated for a significantly longer period of time (median 257 days range 72-603) and a higher cumulative does (P < 0.001). Four patients discontinued intermittent therapy in the period of follow-up, three due to bone marrow suppression. Eight of 13 patients needed red cell transfusions on continuous therapy compared to only one on the intermittent regimen. On intermittent therapy median haemoglobin concentration and neutrophil counts remained stable (Hb median 11.9g dl-1 range 9.1-14.8, neut. median 1.7 x 10 9 1-1 range 0.6-4.3). Ten patients had detectable levels of P24 antigen which decreased from a median of 128pg rnl" (range 15-242) to 24pg rnl" (range 0-53) on continuous therapy. Subsequently, in eight of these patients on the intermittent regimen, levels of P24 Ag remained below 50% of initial pretreatment values (median 28 pg mr' range 0-178) or below 50 pg mr:", Received . 'For correspondence. Tel. +44 71 3809211; Fax +4471 323 0355.
Introduction
The major adverse effect of zidovudine in patients with symptomatic HIV infection is haematological toxicity (Richman et al., 1987) . Approximately 30% of patients on continuous therapy who have severe symptoms of HIV infection will experience a varying degree of anaemia and/or neutropenia (Richman et al., 1987; Dournon et al., 1988; Williams et al., 1989) . This toxicity often leads to permanent discontinuation of treatment, or dose reduction and may require repeated red cell transfusions. Patients with asymptomatic HIVinfection are more able to tolerate zidovudine and the reported incidence of haematological toxicity is much lower (Volberding et el., 1990) .
We report an open study of the use of an intermittent zidovudine regimen in symptomatic patients who were previously unable to tolerate continuous therapy due to haematological toxicity.
Results
As of March 1990, the 13 patients had tolerated a median of 257 days (range 72-603 days) on intermittent therapy. Treatment was discontinued in four patients. In one patient this was due to progressive intrapulmonary Kaposi's sarcoma after 176 days. In the three remaining patients the occurrence of haematological toxicity led to the withdrawal of ZDV (Hb < 9.5g or ', n = 3; neutrophils <0.75 x 10 9 1-1 , n = 2; platelets <24 x 10 9 1-1 , n = 1)after 151, 176 and 439 days. The treatment regimen in these three patients had previously been amended at 72, 157 and 340 days by either reducing the period on zldovudine to two weeks (two patients) or the dose (one patient).
The frequency of haematological adverse events requiring treatment interruption was significantly different between the continuous and intermittent zidovudine treatment periods in the face of a higher cumulative dose taken on the intermittent regimen ( Fig.1a , b)(log rankp < 0.001).
On continuous treatment, the median haemoglobin concentration fell from a pretreatment level of 12.9g dl-1 (range 10.1-15.0) to 7.9g or' (4.9-9.4) at which time treatment was stopped ( Table 1) . Eight of the 13 patients required a red cell transfusion. In contrast the haemoglobin concentration in the majority of patients on the intermittent regimen remained stable ( Fig. 2 ; Table 1) . Similarly, on continuous treatment the neutrophil count fell from a pretreatment value of 2.2 x 10 9 1-1 (range 1.1-5.2) to 0.9, (range 0.3-1.6) at which time treatment was stopped (Table 1, Fig. 3 ). The neutrophil count remained stable on the intermittentregimen.
P24 Ag was detectable in the pretreatment serum in 11 of the 13 patients of whom ten had serum samples taken sequentially whilst on zidovudine therapy. Levels of P24 Ag decreased from a pretreatment median of 128pg ml" Days pattern and range of levels of P24 Ag were more variable. The median level of P24 antigen in these four patients on continuous therapy was 23 pg mr' (range 0-40) but on the intermittent regimen ranged from 0-402 pg ml", median 96pg ml" over the first three cycles of therapy. Of the 13 patients, three developed a major opportunistic infection and one pulmonary Kaposi's sarcoma over the study period. Three of these AIDS defining events occured in the four patients whose serum P24 antigen levels failed to be suppressed on the intermittent regimen. [range 15-242, n = 10j to a median of 24 pg ml-1 (range 0-53) on continuous therapy. On the intermittent regimen, the median level of P24 Ag (average of the last three measured values for each patient) was 28pg mr' (range 0-178, n = 10). In six of these 10 patients the levels of P24 Ag remained below 50% of the initial pretreatment values, whether on or off zidovudine during the cycles of intermittent treatment (Fig. 4 ). In the other four patients, the 140 I. G. Williams et al. who required blood transfusion with intermittent (7.7%, n = 1) vs. continuous treatment (61.5%, n = 8).
A similar reduction in haematological toxicity has previously been observed with an intermittent regimen of zidovudine in patients with ARC or AIDS who had been intolerant on both full and reduced dose daily regimens (Bodsworth et al., 1990) . A regimen of four weeks on therapy (1000-1200mg daily) followed by four weeks off was used and after six months red cell transfusion requirements had been reduced from 65% (13/20) on continuous to 20% (4/20) 011 intermittent therapy.
There are a number of options in the management of zidovudine-induced haematological toxicity. Our study suggests that intermittent therapy may be one such option. Recurrent red cell transfusions are neither practicalor desirable and severe neutropenia with a reported occurrence of 21% (Williams et el., 1989) in severely symptomatic patients treated with zidovudine may still limit tolerance. Alternatively, zidovudine dose can be reduced but haematological toxicity may still occur as it did in two patients in this study, rechallenged with a lower dose.
Although recombinant erythropoietin has now been licensed in the United States for use in patients with zidovudine induced anaemia it is expensive (between £500 and £2000 for a three month course dependant on dose) and furthermore may not be helpful in patients Who develop anaemia without macrocytosis (Fischl et al., 1990) .
The nucleoside analogues, Dideoxyinosine and Dideoxycytidine are currenty in clinical trial, but initial results from surrogate marker data such as CD4 count and P24 antigen From the start of zidovudine therapy the median survival in these four patients was 28.8 months (range 12-32.7) compared to 37.6 (range 19.8-48.6) in the other nine patients. Overall, nine of the 13 patients have died.
Continuous Intermittent
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In patients with severe symptomatic HIV infection haematological toxicity is the main cause of zidovudine intolerance (Richman et al., 1987; Dournon et al., 1988; Williams et aI., 1989) . In this study, 13 patients who had all previously developed severe anaemia on initial treatment were SUbsequently able to tolerate an intermittent regimen of zidovudine which consisted of cycles of four weeks on and two weeks off therapy. The incidence of haematological toxicity requiring discontinuation of therapy was significantly reduced on intermittent zidovudine in the face of a higher cumulative dose compared to the patients' prior experiences on continuous therapy. This reduction in toxicity was reflected in the lower proportion of patients Days Fig. 4 . Individual profiles of P24 Ag (pg ml-1 ) in 6 patients with ARC or AIDS treated with zidovudine initially on continuous therapy (800-1200 mg daily) and then subsequently on an intermittent regimen (four weeks on 600-1000mg daily, two weeks off).
are encouraging. At the moment though we have no good scientific information about their clinical efficacy, in particular whether they are better or worse than zidovudine as monotherapy. Levels of P24 Ag fall in patients treated with zidovudine (Chaisson et et., 1988; Jackson et a/., 1988; Spector et el., 1989; Williams et el., 1990) and this has been taken as evidence of the drug's in vitro antiviral action. Following discontinuation of therapy levels of P24 Ag rise. Furthermore, even in the face of continued therapy P24 Ag levels rise with time (Williams et a/., 1990) and this may be associated with the development of viral resistance. One concern with an intermittent regimen is that the period off treatment in each cycle would allow viral replication associated with an increase in P24 Ag. Although individual profiles of P24 Ag on intermittent therapy in this study suggested that in some patients the range of levels were greater, 6 out of 10 patients had levels of P24 Ag which persistently remained below 50% of pre-treatment values and in two further patients P24 levels remained below 50 pg ml-1 both on and off zidovudine through each cycle of intermittent treatment. However, P24 Ag is only a surrogate marker of viral replication. Alternative methods for measuring the level of viraemia by end point dilution viral cultures (Coombes et aI., 1989; Ho et aI., 1990) or by semi-quantitative PCR (Semple et aI., 1991) may more accurately reflect the efficacy of an intermittent regimen of zidovudine in inhibiting HIV replication.
Although conclusions about overall clinical efficacy cannot be made from the results of this study it does illustrate that intermittent treatment is a therapeutic option in patients who develop early severe haematological toxicity with zidovudine. The results highlight the need for a comparative trial of continuous vs. intermittent zidovudine treatment. However, the window of opportunity for carrying out such a study is rapidly closing with a move towards comparing combinations of drugs to standard therapy, i.e, monotherapy with zidovudine, With the aim of retaining or enhancing efficacy by perhaps retarding the emergence of resistant viruses and improving tolerance by combining drugs with non-overlapping toxicity profiles.
Materials and Experimental procedures
Between August 1988 and March 1930 13 patients developing severehaematologicaltoxicity on continuous zidovudine therapy (800-1200mg daily) were entered into an open study of an intermittent regimen of zidovudine. This consisted of cycles of 4 weeks on therapy followed by 2 weeks off. Six of the 13 patients had an initial diagnosis of ARC and seven had AIDS. All thirteen were homosexual males with a median age of 35.5 years (range 28-51 years). On the initial continuous treatment period the patients tolerated a median of 66 days (range 35-258 days) before discontinuation. The daily dose of zidovudine during this period was 800-1200mg (nine received 1000mg daily, three 1200mgs, and one 800mg). Two of the patients initially on 1200mg had been rechallenged with a lower dose regimen (800mg) and in both the anaemia (Hb < 8.0g or') recurred.
Patientsremainedoff zidovudine for a median of 26 days (range 9-197 days), before starting the intermittent regimen.
This consisted of a daily dose of 600-1000 mg (10 of 13 received 1000mg) given for the first 4 weeks of a 6-week cycle. Seven patients received the same dose of 1000mg on both the continuous and intermittent regimens, for the other six patients the daily dose was reduced by 200mgs (1200-1000mgs, n = 3, 1000mgs-800mgs, n = 2, 800mgs-600mgs, n = 1).
Patients were seen 2-4 weekly and blood samples drawn for measurement of serum P24 antigen (P24 Ag) (Williams et al., , 1990 )and a full blood count. The level of sensitivity for the P24Ag assaywas 10pg ml" , valuesbelow this were regardedas being undetectable. The specificity of reactions for P24 Ag was confirmed by neutralization in all cases.
Statistics
Analysis of proportion of patients remaining on treatment over time or cumulative dose was by Kaplan Meier method and comparison by log rank test. Median and ranges were used for descriptive purposes.
